866-897-8297

Call Is Confidential & Toll Free

Kazano

Kazano is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP -4). Chemically, kazano is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.

Peak inhibition of DPP-4 occurs within 2-3 hours after a single-dose administration to healthy subjects. The peak inhibition of DPP-4 exceeded 93% across doses of 12.5 mg to 800 mg. Inhibition of DPP-4 remained above 80% at 24 hours for doses greater than or equal to 25 mg. Kazano also demonstrated decreases in postprandial glucagon while increasing postprandial active GLP-1 levels compared to placebo over an 8-hour period following a standardized meal. Kazano does not affect the QTc interval.

Common adverse reactions (reported in ≥4% of patients treated with kazano 25 mg and more frequently than in patients who received placebo) are: nasopharyngitis, headache, and upper respiratory tract infection.

Imprints


Drug: Kazano
Strength: 12.5 Mg / 1000 Mg
Pill Imprint: 12.5/1000 322M
Color: Yellow
Shape: Elliptical / Oval

View Images & Details

Drug: Kazano
Strength: 12.5 Mg / 500 Mg
Pill Imprint: 12.5/500 322M
Color: Yellow
Shape: Rectangle

View Images & Details
Disclaimer: We strive to ensure that the content on pilladdictions.com is current and factual at the time it was written. However, because new information and discoveries are always becoming available, we are not making any representations or warranties with respect to this content. Please always rely on the guidance of your physician for information about the drugs you are taking and the impacts they may or may not have on your health.

Questions About Prescription Drug Addiction?

(888) 740-2069

Questions About Prescription Drug Addiction?